Payment overview · 2025
General Payments
$146.10
6 reported records · 5 companies
Healthcare provider profile · identity verified
Alina Rivera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEERFIELD BEACH, FL · NPI 1962809368
Verified facts
What the public records show
CMS Open Payments records show Alina Rivera, MD received $146.10 in general payments during 2025 across 6 reported records.
Exact Sciences Corporation accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.89 | 30.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $30.80 | 21.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.09 | 20.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.27 | 16.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.05 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.10 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 184 |
| Losartan Potassium | Losartan Potassium | 495 | 155 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 97 |
| Omeprazole | Omeprazole | 278 | 92 |
| Metformin Hcl | Metformin Hcl | 262 | 84 |
| Gabapentin | Gabapentin | 216 | 83 |
| Prednisone | Prednisone | 185 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 48 |
| Glimepiride | Glimepiride | 172 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 53 |
| Famotidine | Famotidine | 160 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 47 |
| Simvastatin | Simvastatin | 140 | 44 |
| Metformin Hcl Er | Metformin Hcl | 136 | 44 |
| Mounjaro | Tirzepatide | 130 | 25 |
| Trazodone Hcl | Trazodone Hcl | 124 | 39 |
| Lisinopril | Lisinopril | 122 | 38 |
| Furosemide | Furosemide | 117 | 37 |
| Sertraline Hcl | Sertraline Hcl | 103 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 40 |
| Torsemide | Torsemide | 94 | 33 |
| Allopurinol | Allopurinol | 93 | 30 |
| Carvedilol | Carvedilol | 92 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 84 | 29 |
| Azithromycin | Azithromycin | 80 | 68 |
| Montelukast Sodium | Montelukast Sodium | 75 | 27 |
| Atenolol | Atenolol | 68 | 18 |
| Clonazepam | Clonazepam | 68 | 22 |
| Alprazolam | Alprazolam | 63 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 23 |
| Memantine Hcl | Memantine Hcl | 63 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 14 |
| Levofloxacin | Levofloxacin | 57 | 49 |
| Finasteride | Finasteride | 55 | 13 |
| Eliquis | Apixaban | 51 | 20 |
| Nifedipine Er | Nifedipine | 51 | 20 |
| Spironolactone | Spironolactone | 50 | 17 |
| Azelastine Hcl | Azelastine Hcl | 49 | 31 |
| Glipizide | Glipizide | 49 | 13 |
| Baclofen | Baclofen | 48 | 22 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Meloxicam | Meloxicam | 45 | 19 |
| Mupirocin | Mupirocin | 44 | 30 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 16 |
| Folic Acid | Folic Acid | 42 | 13 |
| Ondansetron Odt | Ondansetron | 42 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Fluconazole | Fluconazole | 40 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Alendronate Sodium | Alendronate Sodium | 34 | 13 |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 16 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Ozempic | Semaglutide | 31 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Leflunomide | Leflunomide | 24 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.10 · 6 records | Exact Sciences Corporation | Cologuard Collection Kit, JARDIANCE, OTEZLA, REPATHA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error